NKGen Biotech Inc (NKGN)

[Cosa]

Very possible to run 1000% or more. Especially while the float is so small and market cap sitting at $26M. Added more today, building a position.

Brief Summary
The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are:

1 - Is SNK01 safe and tolerable when administered every 3 weeks for up to 1 year as an intravenous infusion
2 - Can SNK01 administration improve cognitive assessment scores and biomarkers

Official Title:
A Phase I/IIa, Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Moderate Alzheimer's Disease

Source:
https://clinicaltrials.gov/study/NCT06189963?cond=alzheimer%27s%20disease&intr=SNK01&rank=2